Last reviewed · How we verify
Salbutamol as needed
Salbutamol is a short-acting beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs.
Salbutamol is a short-acting beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs. Used for Asthma, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Salbutamol as needed |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Beta-2 adrenergic receptor agonist |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
This is achieved by binding to beta-2 adrenergic receptors in the bronchial smooth muscle, leading to an increase in cyclic AMP levels and subsequent relaxation of the muscle cells. This results in bronchodilation and improved lung function in patients with asthma or COPD.
Approved indications
- Asthma
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremors
- Nervousness
- Headache
Key clinical trials
- A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (PHASE3)
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (PHASE4)
- A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (PHASE3)
- Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (PHASE3)
- Clinical Assessment of Acupuncture for the Treatment of Chronic Asthma (NA)
- Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma (PHASE4)
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |